Skip to main content
Fig. 1  | Journal of Translational Medicine

Fig. 1 

From: Melatonin as an immunomodulator in CD19-targeting CAR-T cell therapy: managing cytokine release syndrome

Fig. 1 

Melatonin effects on the Raji cell line and primary T cells. A Raji cells were subjected to treatment with melatonin at varying concentrations ranging from 0 to 10 mM for a duration of 24 h. B Raji cells were incubated with 10 mM melatonin for various time-points. The cell viability was measured by MTT assay. C T cells were subjected to treatment with melatonin at varying concentrations ranging from 0 to 10 mM for a duration of 24 h in the presence of interleukin-2 (IL-2, 100 IU/ml). D T cells were incubated with 10 mM melatonin for various time-points in the presence of IL-2 (100 IU/ml). The cell viability was measured by MTT assay. Data are representative of 3 independent experiments. Summary graphs (N = 4) are presented as mean ± SEM, P values were determined by unpaired two-tailed Student’s t-test. *P < 0.05; **P < 0.01; ***P < 0.001

Back to article page